| Literature DB >> 33922418 |
Gyu-Tae Park1, Jung-Won Yoon1, Sang-Bin Yoo1, Young-Chul Song1, Parkyong Song2, Hyoung-Kyu Kim3, Jin Han3, Sung-Jin Bae4, Ki-Tae Ha5, Natalia P Mishchenko6, Sergey A Fedoreyev6, Valentin A Stonik6, Moon-Bum Kim7, Jae-Ho Kim1.
Abstract
Scleroderma is an autoimmune disease caused by the abnormal regulation of extracellular matrix synthesis and is activated by non-regulated inflammatory cells and cytokines. Echinochrome A (EchA), a natural pigment isolated from sea urchins, has been demonstrated to have antioxidant activities and beneficial effects in various disease models. The present study demonstrates for the first time that EchA treatment alleviates bleomycin-induced scleroderma by normalizing dermal thickness and suppressing collagen deposition in vivo. EchA treatment reduces the number of activated myofibroblasts expressing α-SMA, vimentin, and phosphorylated Smad3 in bleomycin-induced scleroderma. In addition, it decreased the number of macrophages, including M1 and M2 types in the affected skin, suggesting the induction of an anti-inflammatory effect. Furthermore, EchA treatment markedly attenuated serum levels of inflammatory cytokines, such as tumor necrosis factor-α and interferon-γ, in a murine scleroderma model. Taken together, these results suggest that EchA is highly useful for the treatment of scleroderma, exerting anti-fibrosis and anti-inflammatory effects.Entities:
Keywords: echinochrome A; fibrosis; inflammation; scleroderma; systemic sclerosis
Year: 2021 PMID: 33922418 DOI: 10.3390/md19050237
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118